Myeloma Patients Europe

Startpagina
België
Brussels
Myeloma Patients Europe

Myeloma Patients Europe is an umbrella organisation of myeloma and AL amyloidosis patient groups

Myeloma Patients Europe (MPE) is an umbrella organisation of myeloma patient groups and associations from across Europe. MPE was formed following the merger in 2011 of the European Myeloma Platform and Myeloma Euronet. MPE is registered as a non-profit organisation (AISBL) under Belgian law and its headquarter is located in Brussels. MPE has a number of broad aims including:
• Collaborating on pro

jects to the benefit of the myeloma community
• Exchanging information and best practice
• Developing existing patient groups and encouraging and facilitating the setting up of new groups
• Helping to shape appropriate health- related policies and initiatives on a European and national level
• Ensuring patients across Europe receive timely access to new treatment
• Stimulating and promoting patient- centred research and clinical trials
• Developing a strong evidence base for the needs and wants of patients and their role in research
• Providing information, educational and outreach programmes to member groups

To meet its aims and in addition to its membership, MPE works directly with healthcare professionals, reimbursement authorities, regulators, politicians, pharmaceutical companies, the media and anyone involved in the ‘myeloma community’.

26/04/2026

The 2026 has concluded. Thank you to all speakers, members and participants who joined us in Lisbon this weekend. We look forward to seeing everyone again in Belgrade in 2027. Oh — and did we mention? Happy 15th birthday to us! 🎂

If you would like to be part of this community, please get in touch with your local member organisation.
Find out more https://f.mtr.cool/allwauczaf

25/04/2026

That's a wrap for day one of the MPE Masterclass 2026. We heard from leading experts on specific treatments, MRD, infection risk, MGUS and collaborated in workshops on next-gen advocacy and AI.

We also held our recognition ceremony of our 2025 ADP graduates and the announcement of 2026 Scholarship recipients. Congratulations to all!

25/04/2026

24/04/2026

The MPE Masterclass poster presentations have officially kick off this year's event!

From mobile mental health support to online expert consultation platforms, our members are doing
extraordinary work across Europe. MPE is proud to support several of these initiatives through our
scholarship programme.

24/04/2026

We’re in Lisbon. The MPE Masterclass 2026 begins today and we couldn't be more excited to welcome all the myeloma patients, advocates, carers, healthcare professionals, researchers and
industry representatives to our Masterclass, where we are celebrating 15 years of myeloma advocacy.
Make sure you are following us on our social media channels for updates over the course of the weekend!
Link to follow us https://t.mtrbio.com/myeloma-patients-europe-mpe-254

22/04/2026

There's no single diet for myeloma, but nutrition does matter — both during treatment and beyond. Some general principles that may help:

- Try to eat a varied diet with plenty of fruit and vegetables
- Staying well hydrated is particularly important, as myeloma can affect the kidneys
- If you're experiencing appetite loss or weight changes, a referral to a dietitian can help
- Some foods and supplements can interact with treatment — always check with your team first

21/04/2026

What is minimal residual disease (MRD) testing in myeloma?
MRD testing is becoming an important tool in myeloma care. Our short video explains what MRD testing is, what your results might mean and how it could affect treatment decisions
https://f.mtr.cool/ypyeznqher

20 likes. "What is Minimal Residual Disease (MRD) in myeloma?"

20/04/2026

We're proud that our President, Barbara Leonardi joined Heather Cooper Ortner last week at in Prague to present on MPE programmes and the importance of including the patient voice in research.

A powerful platform and conversation, in one of Europe’s most beautiful cities.

Great to present with . Thank you to the European Myeloma Network (EMN Trial Office) for inviting us and we look forward to next year!

15/04/2026

Sleep disruption is common for people living with myeloma, whether from pain, medication side effects, anxiety or fatigue. Getting enough rest matters for recovery and wellbeing.

Some approaches that may help:
- Try to keep a regular sleep and wake routine
- Limit screen use before bed
- Exercise during the day
- Gentle relaxation techniques, such as slow breathing, can help settle the mind
- If sleep problems are persistent, it's worth raising with your medical team

14/04/2026

: AL amyloidosis insights

Dr. Paolo Milani provides an expert overview of the most important AL amyloidosis updates presented at ASH 2025, including the emerging role of CAR-T therapy and key challenges in improving treatment outcomes.

Important viewing for the AL amyloidosis community.

Dr. Paolo Milani, University of Pavia, Italy, explains the most important AL amyloidosis updates presented in the American Society of Hematology Annual Congr...

13/04/2026

Did you know? Myeloma is the 3rd most common blood cancer in Europe. During 2022, there were over 50,000 new diagnoses reported alone.

Adres

Avenue Louise 143/4
Brussels
1050

Website

http://www.mpeurope.org/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Myeloma Patients Europe nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.